Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) ...
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 demonstrates 54% cORR, 12.1 months …